EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions

Pilar Velarde, Asmaa Aloufi, David Sanford

Current Oncology · 18.06.2026 · 33 (6) · 369

DOI: 10.3390/curroncol33060369 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 18.06.2026. Verfasst von Pilar Velarde und 2 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplant Program, Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Maintenance Chemotherapy. Die Arbeit nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of acute myeloid leukemia (AML) remains characterized by high relapse rates despite advances in induction and consolidation therapy. Relapse prevention represents a major unmet need, particularly in patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT) or at high risk of post-transplant recurrence. This review examines current evidence supporting maintenance strategies following intensive chemotherapy or allo-HSCT, with emphasis on measurable residual disease (MRD)-guided approaches and targeted therapies. We summarize data from randomized and phase II/III trials evaluating hypomethylating agents, FLT3 inhibitors, IDH inhibitors, and immunotherapeutic strategies in post-remission settings. Oral azacitidine (CC-486) demonstrated overall survival benefit in older patients in first complete remission who were not transplant candidates, establishing a standard of care in this population. In FLT3-mutated AML, post-transplant maintenance with sorafenib and gilteritinib reduces relapse risk, with emerging evidence supporting MRD as a predictive biomarker for benefit. Other targeted agents and immunotherapies have shown promising early-phase results, although confirmatory data are limited. Ongoing phase III studies will clarify optimal patient selection, treatment duration, and integration with transplantation, aiming to transform post-remission management from passive surveillance to precision-based relapse prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMaintenance ChemotherapyHumansHematopoietic Stem Cell Transplantation

Stichwörter der Autor:innen

FLT3 inhibitorsacute myeloid leukemiaallogeneic hematopoietic stem cell transplantationmaintenance therapymeasurable residual diseaseoral azacitidinerelapse preventiontargeted therapy

Autor:innen und Institutionen

  • Bone Marrow Transplant Program, Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada.

Zitieren

APA

Velarde, P., Aloufi, A., & Sanford, D. (2026). Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions. Current Oncology, 33(6), 369. https://doi.org/10.3390/curroncol33060369

Vancouver

Velarde P, Aloufi A, Sanford D. Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions. Current Oncology. 2026;33(6):369. doi:10.3390/curroncol33060369

BibTeX
@article{Velarde2026,
  author = {Velarde, Pilar and Aloufi, Asmaa and Sanford, David},
  title = {Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {6},
  pages = {369},
  doi = {10.3390/curroncol33060369}
}
Kostenlos starten →